Endometriosis is a reproductive condition that occurs when tissue similar to your uterine lining grows outside the uterus, ...

Organon is terminating development of its endometriosis drug after the Phase II trial failed to show any benefit. The ELENA ...

Company executives had seen the drug as a potential multi-billion dollar opportunity in women’s health.

The women’s health focused company acquired the drug for up to $954 million in 2021 through the acquisition of Forendo Pharma.

A landmark 30-year study of over four million women in England has revealed that women with endometriosis-associated ...

Organon will discontinue its OG-6219 clinical-development program, after the investigational candidate failed to meet its primary efficacy endpoint in treating endometriosis-related pain.

Endometriosis is more than just period pain, it’s a progressive disease that can damage vital organs, fertility, and mental ...

A landmark 30-year study of over four million women in England has revealed that women with endometriosis-associated ...

Organon (NYSE:OGN) stock is in focus as the company halts OG-6219 development after a Phase 2 trial in endometriosis-related pain fails. Read more here.

With nearly one third of women impacted by pelvic floor disorders, expanded care access and education from Progyny will help eliminate the silent sufferingNEW YORK, June 24, 2025 (GLOBE NEWSWIRE) -- ...